# Exicure Inc. (XCUR)

Source: https://www.quantisnow.com/company/XCUR
Generated: 2026-11-19T01:11:39.986Z

- Ticker: XCUR
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001698530
- Website: exicuretx.com

## About

Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNAÂbased therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.

## Latest XCUR news and filings

- 2026-11-16 21:00 UTC [Exicure Announces Filing of Notification of Late Filing on Form 12b-25](https://www.quantisnow.com/insight/exicure-announces-filing-of-notification-of-late-filing-on-form-6793858)
- 2026-11-12 19:04 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Exicure Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-exicure-inc-6787353)
- 2026-11-10 20:50 UTC [SEC Form 8-K] [Exicure Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/exicure-inc-filed-sec-form-8-k-entry-into-a-material-6783687)
- 2026-11-10 20:50 UTC [Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion](https://www.quantisnow.com/insight/exicure-inc-announces-agreement-to-sell-gpc-100-program-assets-to-6783686)
- 2026-11-02 22:25 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Exicure Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-exicure-inc-6767901)
- 2026-09-16 14:27 UTC [SEC Form 8-K] [Exicure Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits](https://www.quantisnow.com/insight/exicure-inc-filed-sec-form-8-k-notice-of-delisting-or-6717225)
- 2026-09-16 12:00 UTC [Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement](https://www.quantisnow.com/insight/exicure-receives-nasdaq-extension-to-regain-compliance-with-stockholders-equity-6716913)
- 2026-08-14 19:27 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Exicure Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-exicure-inc-6682857)
- 2026-08-03 13:24 UTC [Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance](https://www.quantisnow.com/insight/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-6659092)
- 2026-07-17 20:39 UTC [SEC Form 4] [Large owner Exicure Hitron Inc. acquired $2,804,738 worth of Common (623,275 units at $4.50), increasing direct ownership by 39% to 2,222,224 units (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-exicure-hitron-inc-acquired-2804738-worth-of-common-6641242)
- 2026-06-30 18:55 UTC [SEC Form 8-K] [Exicure Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/exicure-inc-filed-sec-form-8-k-leadership-update-6620609)
- 2026-06-30 12:40 UTC [Exicure Announces Board and Committee Changes](https://www.quantisnow.com/insight/exicure-announces-board-and-committee-changes-6620197)
- 2026-06-10 20:01 UTC [Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement](https://www.quantisnow.com/insight/exicure-announces-receipt-of-nasdaq-notice-regarding-minimum-stockholders-equity-6596953)
- 2026-06-01 20:00 UTC [Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q](https://www.quantisnow.com/insight/exicure-announces-receipt-of-nasdaq-delinquency-notice-and-filing-of-6581423)
- 2026-06-01 19:30 UTC [SEC Form 8-K] [Exicure Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/exicure-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6581388)
- 2026-05-29 18:09 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Exicure Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-exicure-inc-6578805)
- 2026-05-15 20:01 UTC [SEC Form NT 10-Q filed by Exicure Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-exicure-inc-6556982)
- 2026-04-22 23:54 UTC [Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)](https://www.quantisnow.com/insight/exicure-announces-co-development-agreement-with-adbiotech-for-burixafor-gpc-100-6511111)
- 2026-04-10 20:15 UTC [SEC Form 8-K] [Exicure Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/exicure-inc-filed-sec-form-8-k-leadership-update-6496328)
- 2026-04-02 20:15 UTC [SEC Form 8-K] [Exicure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/exicure-inc-filed-sec-form-8-k-other-events-financial-statements-6484723)
- 2026-03-27 20:40 UTC [SEC Form 8-K] [Exicure Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/exicure-inc-filed-sec-form-8-k-leadership-update-6474973)
- 2026-03-25 20:42 UTC [SEC Form 10-K] [SEC Form 10-K filed by Exicure Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-exicure-inc-6469180)
- 2026-03-25 20:32 UTC [SEC Form 8-K] [Exicure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/exicure-inc-filed-sec-form-8-k-results-of-operations-and-6469131)
- 2026-03-25 20:18 UTC [Dividends] [Exicure, Inc. Reports Full Year 2025 Financial Results](https://www.quantisnow.com/insight/exicure-inc-reports-full-year-2025-financial-results-6469006)
- 2026-02-19 19:27 UTC [SEC Form 4] [Chief Accounting Officer Miller Josh covered exercise/tax liability with 8 shares, decreasing direct ownership by 3% to 301 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-accounting-officer-miller-josh-covered-exercisetax-liability-with-8-6401985)
- 2026-02-17 22:25 UTC [SEC Form 8-K] [Exicure Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/exicure-inc-filed-sec-form-8-k-leadership-update-6397202)
- 2026-02-10 21:25 UTC [SEC Form 8-K] [Exicure Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/exicure-inc-filed-sec-form-8-k-leadership-update-6384381)
- 2026-02-05 12:00 UTC [Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant](https://www.quantisnow.com/insight/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-6376524)
- 2026-01-22 21:29 UTC [SEC Form 8-K] [Exicure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/exicure-inc-filed-sec-form-8-k-other-events-financial-statements-6357914)
- 2026-01-21 17:46 UTC [SEC Form 4] [Large owner Exicure Hitron Inc. sold $1,162,652 worth of shares (258,367 units at $4.50), decreasing direct ownership by 14% to 1,598,947 units (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-exicure-hitron-inc-sold-1162652-worth-of-shares-6355824)
- 2026-01-21 12:00 UTC [Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings](https://www.quantisnow.com/insight/exicure-to-present-data-from-burixafor-phase-2-trial-at-6355163)
- 2026-01-20 22:48 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Exicure Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-exicure-inc-6354813)
- 2026-01-20 19:09 UTC [SEC Form 4] [Large owner Exicure Hitron Inc. sold $3,306,362 worth of Common (734,747 units at $4.50), decreasing direct ownership by 28% to 1,857,314 units (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-exicure-hitron-inc-sold-3306362-worth-of-common-6353876)
- 2026-01-09 01:42 UTC [SEC Form 4] [Large owner Exicure Hitron Inc. sold $3,335,724 worth of Common (741,272 units at $4.50), decreasing direct ownership by 22% to 2,592,061 units (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-exicure-hitron-inc-sold-3335724-worth-of-common-6343632)
- 2025-12-11 01:51 UTC [SEC Form 4] [Large owner Sangsangin Investment & Securities Co., Ltd. sold $3,774,322 worth of shares (433,332 units at $8.71), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-sangsangin-investment-securities-co-ltd-sold-3774322-worth-6311336)
- 2025-12-08 21:30 UTC [Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting](https://www.quantisnow.com/insight/exicure-presents-positive-topline-phase-2-data-for-burixafor-in-6307157)
- 2025-11-19 16:50 UTC [SEC Form 4] [Chief Accounting Officer Miller Josh covered exercise/tax liability with 7 shares, decreasing direct ownership by 2% to 309 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-accounting-officer-miller-josh-covered-exercisetax-liability-with-7-6286603)
- 2025-11-17 21:52 UTC [SEC Form 8-K] [Exicure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/exicure-inc-filed-sec-form-8-k-other-events-financial-statements-6283233)
- 2025-11-10 21:17 UTC [SEC Form 8-K] [Exicure Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/exicure-inc-filed-sec-form-8-k-submission-of-matters-to-6270824)
- 2025-11-07 21:18 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Exicure Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-exicure-inc-6268403)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/XCUR
- Earnings history: https://www.quantisnow.com/earnings/XCUR
- Dividend history: https://www.quantisnow.com/dividends/XCUR
- Insider transactions: https://www.quantisnow.com/insiders/XCUR
- Options chain: https://www.quantisnow.com/options/XCUR
- SEC 8-K filings only: https://www.quantisnow.com/company/XCUR/8-k
- RSS and alerts for XCUR: https://www.quantisnow.com/docs/rss-feeds.md
